{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:24:32Z","timestamp":1790774672161,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Zhejiang Traditional Chinese Medicine Science and Technology Project","award":["2025ZL154"],"award-info":[{"award-number":["2025ZL154"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Toxicol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s12012-025-10088-2","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T06:12:21Z","timestamp":1767939141000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacovigilance Analysis of Sotatercept for the Treatment of Pulmonary Arterial Hypertension Based on FAERS Database"],"prefix":"10.1007","volume":"26","author":[{"given":"Yaxin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianuo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinxia","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"issue":"3","key":"10088_CR1","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1152\/physrev.00030.2021","volume":"103","author":"A Balistrieri","year":"2023","unstructured":"Balistrieri, A., Makino, A., & Yuan, J. X. (2023). Pathophysiology and pathogenic mechanisms of pulmonary hypertension: Role of membrane receptors, ion channels, and Ca(2+) signaling. Physiological Reviews, 103(3), 1827\u20131897.","journal-title":"Physiological Reviews"},{"key":"10088_CR2","doi-asserted-by":"crossref","unstructured":"Humbert, M., Kovacs, G., Hoeper, M. M., Badagliacca, R., Berger, R. M. F., Brida, M., Carlsen, J., Coats, A. J. S., Escribano-Subias, P., Ferrari, P. (2023). 2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 61(1).","DOI":"10.1183\/13993003.00879-2022"},{"key":"10088_CR3","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.2147\/IJGM.S304992","volume":"14","author":"J Chen","year":"2021","unstructured":"Chen, J., Luo, J., Yang, X., Luo, P., Chen, Y., Li, Z., & Li, J. (2021). Transition from Bosentan to ambrisentan in pulmonary arterial hypertension: A Single-Center prospective study. International Journal of General Medicine, 14, 2101\u20132107.","journal-title":"International Journal of General Medicine"},{"issue":"1","key":"10088_CR4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S2213-2600(24)00295-9","volume":"13","author":"GBDPAH Collaborators","year":"2025","unstructured":"Collaborators, G. B. D. P. A. H. (2025). Global, regional, and National burden of pulmonary arterial hypertension, 1990\u20132021: A systematic analysis for the global burden of disease study 2021. Lancet Respir Med, 13(1), 69\u201379.","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10088_CR5","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/s41569-024-01064-4","volume":"22","author":"HA Ghofrani","year":"2025","unstructured":"Ghofrani, H. A., Gomberg-Maitland, M., Zhao, L., & Grimminger, F. (2025). Mechanisms and treatment of pulmonary arterial hypertension. Nature Reviews. Cardiology, 22(2), 105\u2013120.","journal-title":"Nature Reviews. Cardiology"},{"issue":"7","key":"10088_CR6","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1164\/rccm.202009-3698OC","volume":"204","author":"A Boucly","year":"2021","unstructured":"Boucly, A., Savale, L., Jais, X., Bauer, F., Bergot, E., Bertoletti, L., Beurnier, A., Bourdin, A., Bouvaist, H., Bulifon, S., et al. (2021). Association between initial treatment strategy and Long-Term survival in pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine, 204(7), 842\u2013854.","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10088_CR7","doi-asserted-by":"crossref","unstructured":"Sitbon, O., Boucly, A., Weatherald, J., Antigny, F., Guignabert, C., Jevnikar, M., Jais, X., Price, L. C., Wilkins, M. R., Zamanian, R. T. (2025). Drugs targeting novel pathways in pulmonary arterial hypertension. Eur Respir J.","DOI":"10.1183\/13993003.01830-2024"},{"issue":"2","key":"10088_CR8","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S2213-2600(15)00544-5","volume":"4","author":"JD Evans","year":"2016","unstructured":"Evans, J. D., Girerd, B., Montani, D., Wang, X. J., Galie, N., Austin, E. D., Elliott, G., Asano, K., Grunig, E., Yan, Y., et al. (2016). BMPR2 mutations And survival in pulmonary arterial hypertension: An individual participant data meta-analysis. Lancet Respir Med, 4(2), 129\u2013137.","journal-title":"Lancet Respir Med"},{"key":"10088_CR9","doi-asserted-by":"crossref","unstructured":"Yung, L. M., Yang, P., Joshi, S., Augur, Z. M., Kim, S. S. J., Bocobo, G. A., Dinter, T., Troncone, L., Chen, P. S., McNeil, M. E. (2020). ACTRIIA-Fc rebalances activin\/GDF versus BMP signaling in pulmonary hypertension. Sci Transl Med 12(543).","DOI":"10.1126\/scitranslmed.aaz5660"},{"issue":"20","key":"10088_CR10","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMe2503944","volume":"392","author":"BA Maron","year":"2025","unstructured":"Maron, B. A. (2025). Sotatercept and the clinical transformation of pulmonary arterial hypertension. New England Journal of Medicine, 392(20), 2059\u20132061.","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10088_CR11","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/d41573-024-00054-y","volume":"23","author":"K Kingwell","year":"2024","unstructured":"Kingwell, K. (2024). FDA approves Merck & co\u2019s pulmonary arterial hypertension drug Sotatercept. Nature Reviews. Drug Discovery, 23(5), 327.","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10088_CR12","doi-asserted-by":"publisher","first-page":"175346662513428","DOI":"10.1177\/17534666251342898","volume":"19","author":"RA Estrada","year":"2025","unstructured":"Estrada, R. A., Sahay, S., & Tonelli, A. R. (2025). Treatment of pulmonary hypertension after seven world symposia. Therapeutic Advances in Respiratory Disease, 19, 17534666251342898.","journal-title":"Therapeutic Advances in Respiratory Disease"},{"issue":"16","key":"10088_CR13","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","volume":"388","author":"MM Hoeper","year":"2023","unstructured":"Hoeper, M. M., Badesch, D. B., Ghofrani, H. A., Gibbs, J. S. R., Gomberg-Maitland, M., McLaughlin, V. V., Preston, I. R., Souza, R., Waxman, A. B., Grunig, E., et al. (2023). Phase 3 trial of Sotatercept for treatment of pulmonary arterial hypertension. New England Journal of Medicine, 388(16), 1478\u20131490.","journal-title":"New England Journal of Medicine"},{"issue":"20","key":"10088_CR14","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1056\/NEJMoa2415160","volume":"392","author":"M Humbert","year":"2025","unstructured":"Humbert, M., McLaughlin, V. V., Badesch, D. B., Ghofrani, H. A., Gibbs, J. S. R., Gomberg-Maitland, M., Preston, I. R., Souza, R., Waxman, A. B., Moles, V. M., et al. (2025). Sotatercept in patients with pulmonary arterial hypertension at high risk for death. New England Journal of Medicine, 392(20), 1987\u20132000.","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10088_CR15","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.healun.2024.11.037","volume":"44","author":"M Gomberg-Maitland","year":"2025","unstructured":"Gomberg-Maitland, M., Badesch, D. B., Gibbs, J. S. R., Grunig, E., Hoeper, M. M., Humbert, M., Kopec, G., McLaughlin, V. V., Meyer, G., Olsson, K. M., et al. (2025). Efficacy and safety of Sotatercept across ranges of cardiac index in patients with pulmonary arterial hypertension: A pooled analysis of PULSAR and STELLAR. Journal of Heart and Lung Transplantation, 44(4), 609\u2013624.","journal-title":"Journal of Heart and Lung Transplantation"},{"issue":"1","key":"10088_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek, E. P., Bate, A., Leufkens, H. G., Lindquist, M., Orre, R., & Egberts, A. C. (2002). A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiology and Drug Safety, 11(1), 3\u201310.","journal-title":"Pharmacoepidemiology and Drug Safety"},{"issue":"6","key":"10088_CR17","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans, S. J., Waller, P. C., & Davis, S. (2001). Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiology and Drug Safety, 10(6), 483\u2013486.","journal-title":"Pharmacoepidemiology and Drug Safety"},{"issue":"4","key":"10088_CR18","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate, A., Lindquist, M., Edwards, I. R., Olsson, S., Orre, R., Lansner, A., & De Freitas, R. M. (1998). A bayesian neural network method for adverse drug reaction signal generation. European Journal of Clinical Pharmacology, 54(4), 315\u2013321.","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"9","key":"10088_CR19","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/pds.1107","volume":"14","author":"D Banks","year":"2005","unstructured":"Banks, D., Woo, E. J., Burwen, D. R., Perucci, P., Braun, M. M., & Ball, R. (2005). Comparing data mining methods on the VAERS database. Pharmacoepidemiology and Drug Safety, 14(9), 601\u2013609.","journal-title":"Pharmacoepidemiology and Drug Safety"},{"key":"10088_CR20","doi-asserted-by":"crossref","unstructured":"Dardi, F., Guarino, D., Ballerini, A., Bertozzi, R., Donato, F., Cennerazzo, F., Salvi, M., Nardi, E., Magnani, I., Manes, A. (2025). Influence of age in the assessment of therapeutic response in patients with pulmonary arterial hypertension. ERJ Open Res 11(6).","DOI":"10.1183\/23120541.01353-2024"},{"key":"10088_CR21","doi-asserted-by":"publisher","first-page":"108007","DOI":"10.1016\/j.rmed.2025.108007","volume":"240","author":"C Zhang","year":"2025","unstructured":"Zhang, C., Ding, H., Li, J., Ramey, D. R., Zhu, B., Zhou, Z., Yang, M., & Lautsch, D. (2025). Epidemiology, disease burden of pulmonary arterial hypertension in china: A systematic literature review. Respiratory Medicine, 240, 108007.","journal-title":"Respiratory Medicine"},{"issue":"48","key":"10088_CR22","first-page":"823","volume":"120","author":"L Ley","year":"2023","unstructured":"Ley, L., Grimminger, F., Richter, M., Tello, K., Ghofrani, A., & Bandorski, D. (2023). The early detection of pulmonary hypertension. Dtsch Arztebl Int, 120(48), 823\u2013830.","journal-title":"Dtsch Arztebl Int"},{"issue":"1","key":"10088_CR23","doi-asserted-by":"publisher","first-page":"115","DOI":"10.7326\/L23-0387","volume":"177","author":"A Hakim","year":"2024","unstructured":"Hakim, A., Fricker, Z. P., Feuerstein, J. D., Farber, H. W., & Schoenberg, N. C. (2024). Recurrent Gastrointestinal bleeding in a patient with pulmonary arterial hypertension treated with Sotatercept. Annals of Internal Medicine, 177(1), 115\u2013117.","journal-title":"Annals of Internal Medicine"},{"issue":"13","key":"10088_CR24","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1056\/NEJMoa2024277","volume":"384","author":"M Humbert","year":"2021","unstructured":"Humbert, M., McLaughlin, V., Gibbs, J. S. R., Gomberg-Maitland, M., Hoeper, M. M., Preston, I. R., Souza, R., Waxman, A., Escribano Subias, P., Feldman, J., et al. (2021). Sotatercept for the treatment of pulmonary arterial hypertension. New England Journal of Medicine, 384(13), 1204\u20131215.","journal-title":"New England Journal of Medicine"},{"key":"10088_CR25","doi-asserted-by":"crossref","unstructured":"Preston, I. R., Badesch, D., Ghofrani, H. A., Gibbs, J. S. R., Gomberg-Maitland, M., Hoeper, M. M., Humbert, M., McLaughlin, V. V., Waxman, A. B., Manimaran, S. (2025). A Long-Term Follow-Up study of Sotatercept for treatment of pulmonary arterial hypertension: Interim results of SOTERIA. Eur Respir J.","DOI":"10.1183\/13993003.01435-2024"},{"issue":"2","key":"10088_CR26","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.exphem.2012.12.002","volume":"41","author":"C Iancu-Rubin","year":"2013","unstructured":"Iancu-Rubin, C., Mosoyan, G., Wang, J., Kraus, T., Sung, V., & Hoffman, R. (2013). Stromal cell-mediated Inhibition of erythropoiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap. Experimental Hematology, 41(2), 155\u2013166. e117.","journal-title":"Experimental Hematology"},{"issue":"6","key":"10088_CR27","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1111\/bjh.12838","volume":"165","author":"S Carrancio","year":"2014","unstructured":"Carrancio, S., Markovics, J., Wong, P., Leisten, J., Castiglioni, P., Groza, M. C., Raymon, H. K., Heise, C., Daniel, T., Chopra, R., et al. (2014). An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin. British Journal of Haematology, 165(6), 870\u2013882.","journal-title":"British Journal of Haematology"},{"key":"10088_CR28","doi-asserted-by":"publisher","first-page":"115239","DOI":"10.1016\/j.biopha.2023.115239","volume":"165","author":"Z Lan","year":"2023","unstructured":"Lan, Z., Lv, Z., Zuo, W., & Xiao, Y. (2023). From bench to bedside: The promise of Sotatercept in hematologic disorders. Biomedicine & Pharmacotherapy, 165, 115239.","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"10088_CR29","doi-asserted-by":"crossref","unstructured":"Madonna, R., & Ghelardoni, S. (2025). Sotatercept: A crosstalk between pathways and activities in the pulmonary circulation and blood. Int J Mol Sci 26(10).","DOI":"10.3390\/ijms26104851"},{"key":"10088_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.thromres.2016.01.003","volume":"139","author":"XH Zhang","year":"2016","unstructured":"Zhang, X. H., Zhou, S. Y., Feng, R., Wang, Y. Z., Kong, Y., Zhou, Y., Zhang, J. M., Wang, M., Zhao, J. Z., Wang, Q. M., et al. (2016). Increased Prostacyclin levels inhibit the aggregation and activation of platelets via the PI3K-AKT pathway in prolonged isolated thrombocytopenia after allogeneic hematopoietic stem cell transplantation. Thrombosis Research, 139, 1\u20139.","journal-title":"Thrombosis Research"},{"key":"10088_CR31","doi-asserted-by":"crossref","unstructured":"Gasecka, A., Banaszkiewicz, M., Nieuwland, R., van der Pol, E., Hajji, N., Mutwil, H., Rogula, S., Rutkowska, W., Pluta, K., Eyileten, C. (2021). Prostacyclin analogues inhibit platelet Reactivity, extracellular vesicle release and thrombus formation in patients with pulmonary arterial hypertension. J Clin Med 10(5).","DOI":"10.3390\/jcm10051024"},{"key":"10088_CR32","doi-asserted-by":"crossref","unstructured":"Olsson, K. M., Fuge, J., Park, D. H., Kamp, J. C., & Hoeper, M. M. (2025). Withdrawal of Prostacyclin pathway therapies after initiation of Sotatercept treatment in patients with pulmonary arterial hypertension. Eur Respir J 65(6).","DOI":"10.1183\/13993003.00064-2025"},{"key":"10088_CR33","doi-asserted-by":"crossref","unstructured":"Hoeper, M. M., Gomberg-Maitland, M., Badesch, D. B., Gibbs, J. S. R., Grunig, E., Kopec, G., McLaughlin, V. V., Meyer, G., Olsson, K. M., Preston, I. R. (2025). Efficacy and safety of the activin signalling inhibitor, sotatercept, in a pooled analysis of PULSAR and STELLAR studies. Eur Respir J 65(5).","DOI":"10.1183\/13993003.01424-2024"},{"key":"10088_CR34","unstructured":"In. (2024). Sotatercept (Winrevair): Indication: In combination with standard pulmonary arterial hypertension (PAH) therapy, for the treatment of adults with world health organization group 1 PAH and functional class II or III: Reimbursement recommendation. edn. Ottawa (ON)."},{"issue":"2","key":"10088_CR35","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3348\/kjr.2021.0417","volume":"23","author":"HN Lee","year":"2022","unstructured":"Lee, H. N., & Hyun, D. (2022). Pulmonary arteriovenous malformation and its vascular mimickers. Korean Journal of Radiology, 23(2), 202\u2013217.","journal-title":"Korean Journal of Radiology"},{"issue":"9","key":"10088_CR36","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.3324\/haematol.2018.193003","volume":"103","author":"A Kritharis","year":"2018","unstructured":"Kritharis, A., Al-Samkari, H., & Kuter, D. J. (2018). Hereditary hemorrhagic telangiectasia: Diagnosis and management from the hematologist\u2019s perspective. Haematologica, 103(9), 1433\u20131443.","journal-title":"Haematologica"},{"key":"10088_CR37","doi-asserted-by":"crossref","unstructured":"Sanchez-Duffhues, G., & Hiepen, C. (2023). Human iPSCs as model systems for BMP-Related rare diseases. Cells 12(17).","DOI":"10.3390\/cells12172200"},{"issue":"6","key":"10088_CR38","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.cjca.2012.04.009","volume":"29","author":"A Shimony","year":"2013","unstructured":"Shimony, A., Fox, B. D., Langleben, D., & Rudski, L. G. (2013). Incidence and significance of pericardial effusion in patients with pulmonary arterial hypertension. Canadian Journal of Cardiology, 29(6), 678\u2013682.","journal-title":"Canadian Journal of Cardiology"},{"issue":"2","key":"10088_CR39","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1365-2362.2011.02573.x","volume":"42","author":"G Poelzl","year":"2012","unstructured":"Poelzl, G., Ess, M., Mussner-Seeber, C., Pachinger, O., Frick, M., & Ulmer, H. (2012). Liver dysfunction in chronic heart failure: prevalence, characteristics and prognostic significance. European Journal of Clinical Investigation, 42(2), 153\u2013163.","journal-title":"European Journal of Clinical Investigation"},{"issue":"4","key":"10088_CR40","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.cjca.2015.01.023","volume":"31","author":"JJ Ryan","year":"2015","unstructured":"Ryan, J. J., Huston, J., Kutty, S., Hatton, N. D., Bowman, L., Tian, L., Herr, J. E., Johri, A. M., & Archer, S. L. (2015). Right ventricular adaptation and failure in pulmonary arterial hypertension. Canadian Journal of Cardiology, 31(4), 391\u2013406.","journal-title":"Canadian Journal of Cardiology"},{"issue":"4","key":"10088_CR41","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.pcad.2016.12.009","volume":"59","author":"S Vakamudi","year":"2017","unstructured":"Vakamudi, S., Ho, N., & Cremer, P. C. (2017). Pericardial effusions: Causes, Diagnosis, and management. Progress in Cardiovascular Diseases, 59(4), 380\u2013388.","journal-title":"Progress in Cardiovascular Diseases"},{"issue":"142","key":"10088_CR42","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1183\/16000617.0079-2016","volume":"25","author":"KM Olsson","year":"2016","unstructured":"Olsson, K. M., & Channick, R. (2016). Pregnancy in pulmonary arterial hypertension. European Respiratory Reviews, 25(142), 431\u2013437.","journal-title":"European Respiratory Reviews"}],"container-title":["Cardiovascular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-025-10088-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12012-025-10088-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-025-10088-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T02:35:12Z","timestamp":1769222112000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12012-025-10088-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10088"],"URL":"https:\/\/doi.org\/10.1007\/s12012-025-10088-2","relation":{},"ISSN":["1530-7905","1559-0259"],"issn-type":[{"value":"1530-7905","type":"print"},{"value":"1559-0259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"4 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"12"}}